Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size stir an­a­lyst­s' fears — and hopes

To say Gilead’s remde­sivir is in the R&D spot­light would be one of the great un­der­state­ments of the year.

The most ad­vanced late-stage an­tivi­ral …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.